Charles Schwab’s Alimera Sciences ALIM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-50,431
| Closed | -$280K | – | 3628 |
|
|
2024
Q2 | $280K | Buy |
+50,431
| New | +$179K | ﹤0.01% | 3382 |
|
|
2019
Q4 | – | Sell |
-2,627
| Closed | -$23K | – | 3183 |
|
|
2019
Q3 | $23K | Hold |
2,627
| – | – | ﹤0.01% | 3156 |
|
|
2019
Q2 | $36K | Hold |
2,627
| – | – | ﹤0.01% | 3171 |
|
|
2019
Q1 | $42K | Buy |
+2,627
| New | +$40K | ﹤0.01% | 3164 |
|
|
2016
Q2 | – | Sell |
-2,093
| Closed | -$55K | – | 3145 |
|
|
2016
Q1 | $55K | Hold |
2,093
| – | – | ﹤0.01% | 3025 |
|
|
2015
Q4 | $76K | Sell |
2,093
-940
| -31% | -$40.8K | ﹤0.01% | 3056 |
|
|
2015
Q3 | $101K | Hold |
3,033
| – | – | ﹤0.01% | 3032 |
|
|
2015
Q2 | $210K | Hold |
3,033
| – | – | ﹤0.01% | 2970 |
|
|
2015
Q1 | $228K | Hold |
3,033
| – | – | ﹤0.01% | 2922 |
|
|
2014
Q4 | $253K | Hold |
3,033
| – | – | ﹤0.01% | 2910 |
|
|
2014
Q3 | $247K | Hold |
3,033
| – | – | ﹤0.01% | 2878 |
|
|
2014
Q2 | $273K | Hold |
3,033
| – | – | ﹤0.01% | 2894 |
|
|
2014
Q1 | $359K | Sell |
3,033
-1,667
| -35% | -$162K | ﹤0.01% | 2728 |
|
|
2013
Q4 | $333K | Buy |
4,700
+3,087
| +191% | +$126K | ﹤0.01% | 2754 |
|
|
2013
Q3 | $101K | Hold |
1,613
| – | – | ﹤0.01% | 3034 |
|
|
2013
Q2 | $116K | Buy |
+1,613
| New | +$93.1K | ﹤0.01% | 3017 |
|
Charles Schwab's ALIM Position: Q3 2024 in Review
Charles Schwab sold out of Alimera Sciences (ALIM) in Q3 2024, closing a stake of 50,431 shares — an estimated $280K sold.
Charles Schwab first reported a position in ALIM in Q2 2013 and held it in 16 quarters. The position peaked at $359K in Q1 2014. 0 funds tracked by Wall St. Rank hold ALIM as of Q3 2024.
- Charles Schwab reported no remaining Alimera Sciences position as of Q3 2024 after selling out during the quarter.
- Charles Schwab sold 50,431 Alimera Sciences shares in Q3 2024, an estimated $280K.
- Charles Schwab first reported a position in Alimera Sciences in Q2 2013 and held it in 16 quarters.
- Charles Schwab's Alimera Sciences position peaked at $359K in Q1 2014.
- 0 funds tracked by Wall St. Rank held Alimera Sciences as of Q3 2024.
Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.